An integrative proteomics and interaction network-based classifier for prostate cancer diagnosis

PLoS One. 2013 May 30;8(5):e63941. doi: 10.1371/journal.pone.0063941. Print 2013.

Abstract

Aim: Early diagnosis of prostate cancer (PCa), which is a clinically heterogeneous-multifocal disease, is essential to improve the prognosis of patients. However, published PCa diagnostic markers share little overlap and are poorly validated using independent data. Therefore, we here developed an integrative proteomics and interaction network-based classifier by combining the differential protein expression with topological features of human protein interaction networks to enhance the ability of PCa diagnosis.

Methods and results: By two-dimensional fluorescence difference gel electrophoresis (2D-DIGE) coupled with MS using PCa and adjacent benign tissues of prostate, a total of 60 proteins with the differential expression in PCa tissues were identified as the candidate markers. Then, their networks were analyzed by GeneGO Meta-Core software and three hub proteins (PTEN, SFPQ and HDAC1) were chosen. After that, a PCa diagnostic classifier was constructed by support vector machine (SVM) modeling based on the microarray gene expression data of the genes which encode the hub proteins mentioned above. Validations of diagnostic performance showed that this classifier had high predictive accuracy (85.96∼90.18%) and area under ROC curve (approximating 1.0). Furthermore, the clinical significance of PTEN, SFPQ and HDAC1 proteins in PCa was validated by both ELISA and immunohistochemistry analyses. More interestingly, PTEN protein was identified as an independent prognostic marker for biochemical recurrence-free survival in PCa patients according to the multivariate analysis by Cox Regression.

Conclusions: Our data indicated that the integrative proteomics and interaction network-based classifier which combines the differential protein expression and topological features of human protein interaction network may be a powerful tool for the diagnosis of PCa. We also identified PTEN protein as a novel prognostic marker for biochemical recurrence-free survival in PCa patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / metabolism
  • Histone Deacetylase 1 / metabolism
  • Humans
  • Male
  • Middle Aged
  • PTB-Associated Splicing Factor
  • PTEN Phosphohydrolase / metabolism
  • Prostatic Neoplasms / diagnosis*
  • Prostatic Neoplasms / metabolism*
  • Protein Interaction Maps*
  • Proteomics*
  • RNA-Binding Proteins / metabolism
  • Reproducibility of Results

Substances

  • Biomarkers, Tumor
  • PTB-Associated Splicing Factor
  • RNA-Binding Proteins
  • PTEN Phosphohydrolase
  • HDAC1 protein, human
  • Histone Deacetylase 1

Grants and funding

This work was partly funded by National Natural Science Foundation of China (81200550), Chinese National Key Program of Basic Research (2010CB912700, 2011CB910601), National S&T Major Project (2008ZX10002-016, 2009ZX09301-002), National Major Scientific and Technological Special Project (2011ZX09307-304), Science and Technology Project of Guangdong Province (2010B060500003), Guangzhou Municipal Science and Technology Key Project (2010Y1-C041). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.